Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 632

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 632
---
 has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. Unless otherwise indicated, Denali believes, based on information available to it, that all persons named in the table below have sole voting and investment power with respect to all Denali Ordinary Shares beneficially owned by them. The beneficial ownership of Denali Ordinary Shares pre-Business Combination is based on 2,616,239 Denali Ordinary Shares issued and outstanding as of June 30, 2025 (consisting of 29,117 Denali Class A Ordinary Shares, 14,622 Denali Class A Ordinary Shares underlying the Public Units, 510,000 Denali Private Placement Shares underlying the Denali Private Placement Units and 2,062,500 Denali Class B Ordinary Shares). The beneficial ownership of securities pre-Business Combination and post-Business Combination excludes the shares underlying the Public Warrants and the Denali Private Placement Warrants because those securities are not exercisable within 60 days of this proxy statement/prospectus. The expected beneficial ownership of New Semnur Common Stock and New Semnur Preferred Stock post-BusinessCombination set forth below reflects a “no redemptions” scenario and a “maximum redemptions” scenario.

| • |     | Under the “no redemptions” scenario, the expected beneficial ownership of New Semnur Common Stock and New Semnur Series A Preferred Stock immediately following the closing of the Business Combination has been determined based on the following assumptions: (i) that none of the 43,739 public shares (consisting of (a) 29,117 Denali Class A Ordinary Shares and (b) 14,622 Denali Class A Ordinary Shares underlying the Public Units) are redeemed; (ii) that none of the investors set forth in the table below has purchased or purchases shares of Denali Ordinary Shares (pre-Business Combination) or New Semnur Common Stock or New Semnur Series A Preferred Stock (post-Business Combination); (iii) that a maximum of 6,000,000 shares of New Semnur Series A Preferred Stock are issued in the Business Combination as Preferred Consideration; and (iv) that there will be an aggregate of 234,126,025 shares of New Semnur Common Stock issued and outstanding, which number of shares of New Semnur Common Stock is comprised of (a) the